LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
STANDARD BIOTOOLS INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | $135.79M | $63.88M | $52.50M | $67.66M | – | – | – | – | – | – | – |
| Genomics | – | $38.64M | $42.46M | $45.45M | $62.92M | – | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | -$61.90M | -$21.41M | -$27.39M | -$10.92M | – | – | – | – | – | – |
| Genomics | – | $3.20M | -$106.00K | -$25.61M | -$10.20M | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $61.66M | $65.43M | $79.20M | $72.45M | $100.38M | $99.94M | $95.42M | $93.65M | $84.40M | $89.00M | 72.3% | -5.8% |
| Consumables | $36.25M | $40.54M | $41.74M | $46.79M | $57.88M | $54.41M | $45.41M | $48.16M | $41.89M | $42.17M | 42.5% | -10.6% |
| Instruments | $25.41M | $24.89M | $37.46M | $25.66M | $42.50M | $45.54M | $50.00M | $45.49M | $42.51M | $46.83M | 29.8% | +2.1% |
| Services and other revenue | $23.67M | $25.58M | $27.14M | $25.49M | – | – | – | – | – | – | 27.7% | -7.5% |
| Services and other revenue | $23.67M | $25.58M | $27.14M | – | – | – | – | – | – | – | 27.7% | -7.5% |
| License and royalty revenue | – | – | – | $964.00K | $147.00K | $3.16M | $0 | $0 | $190.00K | $238.00K | – | – |
| Service revenue | – | $81.13M | $25.98M | $23.71M | $25.92M | $22.58M | $21.28M | $19.31M | $17.35M | $15.21M | – | – |
| Grant revenue | – | – | – | – | – | – | $550.00K | $0 | $0 | – | – | – |
| Development revenue | – | – | – | $818.00K | $2.56M | $8.87M | $0 | $0 | – | – | – | – |
| Other revenue | – | – | $1.16M | $1.78M | $1.73M | $6.76M | $550.00K | $0 | – | – | – | – |
| Grant revenue | – | – | – | $0 | $1.58M | $3.59M | $550.00K | $0 | – | – | – | – |
| Product and service revenue | – | $169.70M | $105.18M | $96.17M | $126.29M | – | – | – | – | – | – | – |
| Collaboration and other revenue | – | $4.73M | $1.16M | $1.78M | – | – | – | – | – | – | – | – |
| Instrument support services | – | $24.65M | $25.27M | $23.22M | – | – | – | – | – | – | – | – |
| Assay services | – | $56.48M | $706.00K | $493.00K | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $35.99M | $35.65M | $36.20M | $33.14M | $42.72M | $37.78M | $40.02M | $36.62M | $32.64M | $29.74M | 42.2% | +0.9% |
| Americas | $30.56M | $37.40M | $46.20M | $43.98M | $63.88M | $74.59M | $47.02M | $51.17M | $49.29M | $56.23M | 35.8% | -18.3% |
| Asia-Pacific | $18.78M | $17.96M | $23.94M | $20.83M | $23.98M | $25.78M | $30.20M | $25.18M | $20.01M | $18.48M | 22.0% | +4.6% |
| United States | – | – | – | – | – | – | – | – | $45.82M | $52.64M | – | – |
| Other | – | – | – | – | – | – | – | – | $3.47M | $3.59M | – | – |
| Europe | – | – | – | – | – | – | – | – | $32.64M | $29.74M | – | – |
From the segment and revenue-disaggregation notes of Standard Biotools's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.